Table 2.
Cost-effectiveness analysis
| Strategies | Life years | Total costs ($) | QALYs | ICER, $/QALY |
|---|---|---|---|---|
| A | ||||
| NI | 2.01 | 46,362 | 1.30 | 375,656 |
| C | 1.89 | 8339 | 1.20 | |
| Incremental (NI vs. C) | 0.12 | 38,023 | 0.10 | |
| E | ||||
| NI | 2.01 | 46,598 | 1.44 | 327,943 |
| C | 1.89 | 8596 | 1.33 | |
| Incremental (NI vs. C) | 0.12 | 38,002 | 0.12 | |
| N | ||||
| NI | 2.01 | 46,232 | 1.24 | 115,495 |
| C | 1.89 | 7689 | 0.90 | |
| Incremental (NI vs. C) | 0.12 | 38,543 | 0.33 | |
QALY Quality-adjusted life year, ICER Incremental cost-effectiveness ratio, A All randomized patients, E Patients with epithelioid histology, N Patients with non-epithelioid histology, NI Nivolumab plus ipilimumab, C Pemetrexed plus cisplatin/carboplatin